Assessing the effectiveness of dermatological treatments: Why choosing the right endpoints matters?

TYPES OF ENDPOINTS IN DERMATOLOGY

Endpoints in clinical trials can be broadly classified into primary, secondary, and exploratory endpoints.

1. Primary Endpoints: These are the main outcomes used to assess the effectiveness of a treatment. In dermatology, common primary endpoints include lesion count reduction in acne studies, Psoriasis Area and Severity Index (PASI) improvement in psoriasis trials, and Investigator’s Global Assessment (IGA) scores for eczema.^[1,2]

2. Secondary endpoints: These provide an additional insights into treatment effects and include patient-reported outcomes (e.g., Dermatology Life Quality Index [DLQI]), duration of remission, and safety measures.^[3]

3. Exploratory endpoints: These are used to generate hypotheses for future research and may include biomarkers or novel imaging techniques.

OBJECTIVE VERSUS SUBJECTIVE ENDPOINTS

Endpoints in dermatology can be objective or subjective.

• Objective endpoints: These include lesion counts, PASI scores, and histopathological findings, which provide quantifiable measures of disease severity.^[2] They reduce bias and ensure reproducibility.

• Subjective endpoints: These include patient-reported outcomes such as pruritus severity and quality of life assessments. While subjective, these measures are crucial in chronic dermatological conditions where patient perception of improvement is significant.^[3,4]

Table 1 lists a comparison of common endpoints in dermatology trials.

CHALLENGES IN SELECTING THE RIGHT ENDPOINTS

1. Inter-observer variability: Dermatological conditions often rely on visual assessments, leading to potential variability in scoring. Standardized scoring systems and digital imaging can help mitigate this issue. Studies have shown that formal training can reduce inter-rater and intra-rater variability in PASI assessment, with standardized photographic training reducing inter-observer variability from 15.8% to 8.9%.^[5] However, complete elimination of subjective variabilities remains challenging.

2. Placebo effect: Many dermatological conditions, such as atopic dermatitis, have a high placebo response rate. Meta-analysis data show that at 12-week follow-up, EASI50, EASI75, and EASI90 placebo responses in atopic dermatitis trials were 39.9%, 20.9%, and 9.0%, respectively.^[6] Using robust endpoints with adequate control groups helps differentiate true treatment effects from placebo responses.

3. Long-term efficacy versus short-term improvement: Some treatments provide rapid symptom relief but lack long-term efficacy. Selecting endpoints that measure sustained improvement, such as relapse rates or time to disease flare, is essential for comprehensive treatment evaluation.^[7]

REGULATORY CONSIDERATIONS

Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency, have specific guidelines on acceptable endpoints for dermatological trials. For example, the FDA considers a 75% reduction in PASI (PASI 75) as a clinically meaningful endpoint for psoriasis treatments.^[8] Patient feedback from FDA meetings emphasizes that meaningful improvement includes not only clinical measures but also quality of life improvements and reduction in treatment burden.^[8] Selecting validated and widely accepted endpoints is crucial for regulatory approval and clinical adoption.

PATIENT-CENTERED OUTCOMES

Recent emphasis has been placed on patient-oriented treatments for chronic inflammatory skin diseases.^[7] This approach recognizes that traditional clinical endpoints may not fully capture the patient experience. Patient-reported outcome measures such as the DLQI have become increasingly important in clinical trials and clinical practice.^[3] The integration of both physician-assessed and patient-reported endpoints provides a more comprehensive evaluation of treatment effectiveness.

DIGITAL INNOVATION IN ENDPOINT ASSESSMENT

Emerging digital technologies are revolutionizing endpoint assessment in dermatology. Artificial intelligence-based severity assessments and digital imaging techniques are improving the objectivity and reproducibility of traditional scoring systems.^[5] These innovations may help address inter-observer variability while maintaining the clinical relevance of established endpoints.

CONCLUSION

Choosing the right endpoints in dermatology clinical trials is essential for accurate assessment of treatment efficacy. Researchers should prioritize clinically meaningful, reproducible, and patient-centered outcomes to ensure robust and applicable study results. A combination of objective measures and patient-reported outcomes provides a comprehensive evaluation of therapeutic effectiveness. As the field evolves, incorporating digital innovations and maintaining focus on patient-centered care will further enhance the relevance and reliability of clinical endpoints in dermatological research.